Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly docetaxel with daily low-dose prednisone and cyclophosphamide in hormone-refractory prostate carcinoma
2006-003585-34Phase 2Completed
- Start
- Oct 2006
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cyclophosphamide and prednisone in prostate cancer (PCa). Primary endpoints: Overall response rate and Tolerability. Started Oct 2006; status: completed.
02
Drugs
docetaxelcyclophosphamideprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-003585-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003585-34.